Results 171 to 180 of about 82,034 (275)

How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data

open access: yesCancer, Volume 132, Issue 16, 15 August 2026.
In a retrospective analysis of Veterans Health Administration data for patients with metastatic castration‐sensitive prostate cancer (mCSPC), achieving a prostate‐specific antigen (PSA) of <0.2 ng/mL (whether or not a PSA decline of 90% was reached) within 9 months of initiating androgen deprivation therapy (ADT) ± other treatments was associated with ...
Stephen J. Freedland   +7 more
wiley   +1 more source

Long-term function and oncologic outcomes following nerve spare or wide resection during radical prostatectomy. [PDF]

open access: yesCan Urol Assoc J
Nayak AL   +8 more
europepmc   +1 more source

A single-center study of prognostic impact and treatment implications of cribriform pattern in prostate cancer. [PDF]

open access: yesDiscov Oncol
Handke A   +7 more
europepmc   +1 more source

Perineal Prostatectomy

open access: yesInternational Journal of Clinical Practice, 1973
openaire   +2 more sources

Home - About - Disclaimer - Privacy